Review article: Esomeprazole - Enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 4, 2003, Pages 481-488

  Lindberg, P ^a   Keeling, D ^b   Fryklund, J ^a   Andersson, T ^b   Lundborg, P ^a   Carlsson, E ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; AREA UNDER THE CURVE; DEPRESSION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; ISOMER; MALAISE; MYALGIA; NAUSEA; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; VOMITING;

ANTI-ULCER AGENTS; BIOLOGICAL AVAILABILITY; GASTRIC ACID; HUMANS; OMEPRAZOLE; PROTON PUMPS;

EID: 0344255711     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01481.x     Document Type: Review

References (57)

1. 2-antagonists alone completely block food-stimulated acidity? Eur J Gastroenterol Hepatol 1991: 3: 533-7.
2. 2-antagonist treatment. Gastroenterology 1991; 101: 599-606.
3. 2-receptor antagonists. Scand J Gastroenterol 1989: 24(Suppl. 166): 88-93.
4. Bardhan K. Omeprazole in the management of refractory duodenal ulcer. Scand J Gastroenterol 1989; 166: 63-73.
5. 2-receptor blockade. Gut 1991; 32: 1455-60.
6. Nwokolo C, Smith J, Gavey C, Sawyerr A, Pounder R. Tolerance during 29 days of conventional dosing with cimetidine. nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4(Suppl. 1): 29-45.
7. Blum AL. Treatment of acid-related disorders with gastric acid inhibitors: the state of the art. Digestion 1990; 47(Suppl. 1): 3-10.
8. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux oesophagitis. Results of a double-blind, randomized Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625-32.
9. Sachs G. Proton pump inhibitors and acid-related disease. Pharmacotherapy 1997; 17: 22-37.
10. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
11. Howden C, Burget D, Hunt R. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol 1993; 29(Suppl. 201): 79-82.
12. Langtry H, Wilde M. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by non-steroidal anti-inflammatory drugs. Drugs 1998; 56: 447-86.
13. Holloway R, Dent J, Narielvala F, Mackinnon A. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-54.
14. Carlsson E, Lindberg P, von Unge S. Two of a kind. Chem Br 2002; 38: 42-5.
15. Erlandsson P, Isaaksson R, Lorentzon P, Lindberg P. Resolution of the enantiomers of omeprazole and some of its analogues by liquid crystal chromatography on a trisphenylcarbamoylcellulose-based stationary phase. The effect of the enantiomers of omeprazole on gastric glands. J Chromatogr 1990; 532: 305-19.
16. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411-26.
17. Äbelö A, Andersson T, Antonsson M, Naudot A. Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966-72.
18. Andersson T, Bredberg E, Sunzel M, Antonsson M, Weidolf L. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O). Gastroenterology 2000; 118: A1210(Abstract).
19. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole. Aliment Pharmacol Ther 2001; 15: 1563-9.
20. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
21. Lindberg P, Brändstrom A, Wallmark B, et al. Omeprazole: the first proton pump inhibitor. Med Res Rev 1990; 10: 1-54.
22. Helander HF, Ramsay C-H, Regårdh C-G. Localization of omeprazole and metabolites in the mouse. Scand J Gastroenterol 1985; 20(Suppl. 108): 95-104.
23. +-ATPase by omeprazole. Biochem Pharmacol 1988; 37: 2543-9.
24. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6.
25. Regårdh C-G, Gabrielsson M, Hoffman K-L, Löfberg I, Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand J Gastroenterol 1985; 20(Suppl. 108): 79-94.
26. Wilder-Smith C, Röhss K, Lundin C, Rydholm H. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000; 118: A22-3.
27. Thomson A, Claar-Nilsson C, Hasselgren G, Niazi M, Röhss K, Nyman L. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut 2000; 47(Suppl. 3): A63 (Abstract).
28. Wilder-Smith C, Claar-Nilsson C, Hasselgren G, Röhss K. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GORD. J Gastroenterol Hepatol 2002; 17(Suppl.): A612 (Abstract).
29. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954-8.
30. Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 57-77.
31. Kahrilas P, Falk G, Johnson D, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomised controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-58.
32. Richter J, Kahrilas J, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
33. Castell D, Kahrilas P, Richter J, et al. Esomeprazole 40 mg compared with lansoprazole 30 mg on the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
34. Vakil N, Shaker R, Johnson D, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis. A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 926-35.
35. Johnson D, Benjamin S, Vakil N, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34.
36. Lauritsen K, Junghard O, Eklund S. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed reflux esophagitis. J Gastroenterol Hepatol 2002; 17(Suppl.): A1007 (and associated poster).
37. Nilsson A, Torvén A, Sohtell M. Lack of effect of omeprazole on kidney function in hypokalemic rats expressing increased mRNA levels for a renal H,K-ATPase. Gastroenterology 1995; 108(Suppl.): A179(Abstract).
38. Futai M, Oka T, Sun-Wada G-H, Moriyama Y, Kanazawa H, Wada Y. Luminal acidification of diverse organelles by V-ATPase in animal cells. J Exp Biol 2000; 203: 107-16.
39. Kromer W. Relative efficacies of gastric proton pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol 2001; 234(Suppl.): 3-9.
40. Kromer W, Kruger U, Huber R, Hartmann M, Steinjans V. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998; 56: 57-70.
41. Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S35-41.
42. Uhlig S, Wendel A. The physiological consequences of glutathione variations. Life Sci 1992; 51: 1083-94.
43. Rossi R, Milzani A, Dalle-Donne I, et al. Blood glutathione disulfide: in vivo factor or in vitro artifact? Clin Chem 2002; 48: 742-53.
44. Andersson T, Cederberg C, Heggelund A, Lindberg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45-52.
45. +)-ATPase inhibitor depends upon the means of its activation. Biochem Pharmacol 1987; 36: 339-44.
46. +)-ATPase inhibitor. Biochem Pharmacol 1990; 39: 1799-806.
47. +-translocating ATPases. Biochim Biophys Acta 1991; 1065: 261-8.
48. +) ATPase, on hepatic lysosomal integrity and enzyme activity. J Pharm Pharmacol 1986; 38: 158-60.
49. Maton P, Vakil B, Hwang C, Skammer W, Hamelin B, Lundborg P. The safety and efficacy of long-term esomeprazole therapy in patients with healed erosive esophagitis. Drug Saf 2001; 24: 625-35.
50. Creutzfeldt W. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. Drug Saf 1994; 10: 66-82.
51. Joelson S, Joelson I-B, Lundborg P, Wala A, Wallander M-A. Safety experience from long-term treatment with omeprazole. Digestion 1992; 51(Suppl. 1): 93-101.
52. Sölvell L. The clinical safety of omeprazole. Digestion 1990; 47(Suppl. 1): 59-63.
53. Klinkenberg-Knol E, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
54. Lloyd-Davies K, Rutgersson K, Sölvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Aliment Pharmacol Ther 1988; 2: 13-32.
55. Metz D, Strader D, Orbuch M, Koviack P, Feigenbaum K, Jensen R. Use of omeprazole in Zollinger-Ellison syndrome: a prospective 9-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-610.
56. Lundell L, Miettinen P, Myrvold H, et al. Continued (5 year) follow up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172-81.
57. Martin R, Dunn N, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50: 366-72.